Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673127 · ClinicalTrials.gov registry record · Phase 2
Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00673127 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 57 participants.
The verdict
NCT00673127, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. The purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will make the combination more effective in treating prostate cancer.
Interventions
- DRUG Ketoconazole, Hydrocortisone and Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673127
The ClinicalTrials.gov registry entry for NCT00673127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketoconazole, Hydrocortisone and Dutasteride is the first listed.
NCT00673127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673127 about?
NCT00673127 is a clinical study titled "Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer". The combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. The purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will make the combination more effective in treating prostate cancer.
What is the current status of trial NCT00673127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2005-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00673127?
The interventions under investigation include: Ketoconazole, Hydrocortisone and Dutasteride (DRUG).
Who is sponsoring clinical trial NCT00673127?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.